{"entity":{"id":"cegat","kind":"company","name":"CeGaT","aka":[],"tldr":"CeGaT, a Tübingen genetics laboratory, sequences tumour and normal DNA side by side and identifies the patient-specific neoantigens that personalised vaccines are built on.","summary":"CeGaT has run genetic analyses for medical, research and pharmaceutical customers since 2009. Its tumour diagnostics compare tumour and germline sequences to find somatic alterations and, from them, patient-specific neoantigens; the personalised peptide vaccine programme at CeCurio, the MVZ Tübingen oncology practice, draws on that work. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://cegat.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tübingen, Germany","country":"DE","companyType":"diagnostics","website":"https://cegat.com/","investors":[],"funding":[]},"route":"/companies/cegat/","neighbours":{"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}]}}